Fungal Surveillance in Bangladesh
Recruiting now
Conditions studied: Invasive Fungal Infections
In brief
This will be an exploratory descriptive study designed to conduct surveillance for the identification of invasive fungal pathogens among hospitalized patients in Bangladesh at two tertiary care acute-level hospitals. including the Dhaka Medical College Hospital, the Dhaka Hospital of icddr,b, and the National Institute of Cancer Research Hospital (NICRH). Respiratory samples, blood, urine, cerebrospinal fluid, surgical wound infection swabs, and other samples including biopsy tissue specimens will be obtained at intensive care units, general medicine and surgery wards, post-operative care, etc. The collected specimens will be sent to the clinical microbiology laboratories of the surveillance hospitals or to the pathology laboratory (biopsy tissue specimens) to test for Aspergillus, Histoplasms, Candida, Pneumocystis, Cryptococcus, and Mucormycetes. The lab. methods will include microscopy, staining, culture, and biochemical tests mainly and if feasible then some specimens may undergo molecular or immunological methods.
Key facts
- Study ID
- NCT06103331
- Run by
- International Centre for Diarrhoeal Disease Research, Bangladesh
- People needed
- 800
- Starts
- 2022-01-20
- Expected to finish
- 2026-09-30
- Last updated by the study team
- 2023-11-22
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Inclusion criteria:
- Must include all of the following criteria:
- Admitted/hospitalized patients of any age and gender in tertiary-level acute care hospitals AND
- Having any of the following co-morbid immunosuppressive conditions or risk factors for healthcare-associated fungal infections such as:
- Chronic lung conditions including asthma, COPD
- Hemodialysis patients,
- diabetes,
- Patients receiving chemotherapy or immunosuppressive drugs (e.g. corticosteroids, immunosuppressive drugs among organ transplant recipients), for ≥7 days
- Patients with AIDS
- Patients at risk of healthcare-associated infections (e.g., Patients under postoperative care, having a urinary catheter, with tracheal intubation, under ventilatory support, secured with intravenous (IV) cannula, any other invasive procedures, etc.)
- Hospitalized Patients under prolonged injectable antibiotic treatment (>7 days)
- Prolonged hospitalization more than 7 days.
- History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization
- AND
- Patients or caregivers providing consent
- For children aged <5 years, the age criteria and additional inclusion criteria will be as follows:
- 0 to 59-month-old children of either sex admitted in hospital with any illness.
- Have features of sepsis/pneumonia (based on clinical features below)
- And any of the following criteria:
- Those who will fail to respond to injectable antibiotics or both 1st and 2nd line antibiotics (1st line- inj. Ampicillin plus gentamicin, 2nd line- inj. Ceftriaxone plus levofloxacin/gentamicin as per icddr,b hospital protocol)
- Any child with SAM or h/o recent measles or any condition that may induce immune suppression plus fail to respond to injectable antibiotics/ 1st line antibiotics (1st line antibiotics- inj. Ampicillin +inj. Gentamicin)
- Those who will develop late-onset hospital-associated infection (LOHAI)
- Any child who will require ICU care for more than 7 days
- Develop extensive thrush after taking long-term injectable antibiotics
- History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization
You may not qualify if…
- History of taking antifungal drugs within 2 weeks
- Not willing to give consent
Where it is running
- International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) — Dhaka, Bangladesh (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.